-
Peijia Medical Achieves Milestone with First Commercial Implants of Trilogy TAVR System in Hong Kong
•
Peijia Medical Limited (HKG: 9996), a leading China-based medical device company, has announced the successful completion of the first two commercial implants using its transcatheter aortic valve replacement (TAVR) product, the Trilogy heart valve system, in Hong Kong. This marks a significant milestone as the Trilogy system is the first…
-
BiOneCure Therapeutics and Nanjing Leads Biolabs Collaborate on Innovative ADCs for Solid Tumors
•
US-based biotech company BiOneCure Therapeutics Inc. has entered into a strategic collaboration with China-based Nanjing Leads Biolabs. The partnership aims to develop a range of innovative antibody drug conjugates (ADCs) that target solid tumors, marking a significant step in the advancement of cancer treatments. Combining Expertise to Target Solid TumorsBiOneCure…
-
Lynk Pharmaceuticals’ LNK01001 Demonstrates Efficacy in Phase II Rheumatoid Arthritis Study
•
China-based Lynk Pharmaceuticals Co., Ltd announced positive results from the Phase II clinical study of its drug candidate LNK01001 in treating rheumatoid arthritis (RA). The study demonstrated a statistically significant efficacy difference in terms of primary and key secondary endpoints, along with a favorable safety and tolerability profile. LNK01001: A…
-
Skyline Therapeutics Initiates Clinical Study with First Patient Dosing of SKG0106 for wAMD
•
Skyline Therapeutics has reached a significant milestone with the completion of the first patient dosing in its clinical study for SKG0106 intraocular injection solution. This in-house developed ophthalmology gene therapy was approved for clinical trials in China in December 2022. The open, dosage escalation study is designed to evaluate the…
-
Gracell Biotechnologies Initiates Trial for GC012F in Refractory SLE with Dual-Target FasTCAR Therapy
•
Gracell Biotechnologies Inc., (Nasdaq: GRCL), a China-based biopharmaceutical company, has announced the start of an investigator-initiated trial (IIT) in China for its therapeutic candidate GC012F. This candidate is an autologous FasTCAR therapy aimed at treating refractory systemic lupus erythematosus (SLE). The therapy is distinctive as a dual B cell maturation…
-
Aligos Therapeutics Partners with Amoytop Biotech for Oligonucleotide Compound R&D
•
Liver and viral disease specialist Aligos Therapeutics (NASDAQ: ALGS) announced last week a significant partnership with biopharmaceutical company Xiamen Amoytop Biotech (SHA: 688278) for the research and development (R&D) of live disease-targeting oligonucleotide compounds. These compounds are discovered using Aligos’s proprietary platform, marking a step forward in the treatment of…
-
CIM’s Cancer Vaccine CIMAvax Confirmed Immunogenic in US Study, Cuba Announces
•
The Cuba-based Molecular Immunology Center (CIM), part of the state-run conglomerate BioCubaFarma, has shared updates on the status of clinical trials (CTs) for two of its drug candidates being conducted abroad. CIM Director Tania Crombet revealed that a US study, in collaboration with the Roswell Park Cancer Institute, has confirmed…
